The HIV prevention drug, Truvada, is a once-daily pill developed by Gilead Sciences. (AAP) Tweet Facebook Mail A HIV prevention drug will not be taxpayer-subsidised after it failed to receive recommendation to the Pharmaceutical Benefits Scheme.An application to list Truvada, a once-daily pill aimed at preventing HIV transmission, was yesterday rejected by the Pharmaceutical Benefits Advisory Committee.The Department Of Health claimed the AU$750 price requested by the maker, Gilead Sciences, was far too high. "The PBAC would welcome another submission... addressing its concerns about cost effectiveness and the appropriate eligible population," a government spokeswoman told AAP.The Australian Federation of AIDS Organisations urged Gilead Sciences to submit another application."People are needlessly getting HIV while we wait for access to this prevention pill," chief executive Darryl O'Donnell said.Greens leader Richard Di Natale urged the Australian government to reconsider the decision.RelatedRush to publish COVID-19 research saw errors in top medical journals triple, study findsNew health alert in South Australia after positive COVID-19 case breached quarantineTwo new coronavirus cases reported in South Australia"It costs an individual about $1200 each year to import this medication, which simply isn't possible for many Australians who are at risk of HIV transmission," Mr Natale said."We simply cannot leave Australians at unnecessary risk, when this drug gives us the chance to end HIV transmission in Australia."With AAP
Us apple developer accounts for sale
buyappleacc.com is a reputed website selling apple developer account, providing us, China and worldwide developer individual accounts for sale. It's at low price and good quality. Always provides satisfying services!